secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2023-04-12T23:59:59+00:00
Accession:  0001438533-23-000012
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Therapeutics dismisses BDO as auditor, appoints EY; discloses material weakness in internal controls
--------------------------------------------------------------------------------

- BDO dismissed as independent auditor effective April 6, 2023; EY appointed for fiscal year ending Dec 31, 2023.
- BDO's audit reports for FY2022 and FY2021 were unqualified with no adverse opinion or modifications.
- Disclosed material weakness in controls over pre-launch inventory contract affecting R&D expense timing; no restatement required.
- No disagreements with BDO on accounting principles or audit scope during 2022, 2021, or interim period through April 6, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853323000012/0001438533-23-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853323000012/tvtx-20230406.htm
  HTML page:      https://secwatch.observer/filing/0001438533-23-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer